Sherwell Biotech

Sherwell Biotech is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide medicines for metabolic diseases. The company leverages its proprietary peptide engineering platform to create multi-targeting agonists, such as its lead candidate SW-101. SW-101 is a long-acting GLP-1/GIP/GCG triple receptor agonist currently being evaluated in clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Based in Hong Kong and Suzhou, Sherwell Biotech focuses on addressing significant unmet needs in the global metabolic health landscape. The company's approach aims to provide superior weight loss and metabolic benefits compared to existing mono- or dual-agonist therapies. Sherwell is led by an experienced management team with deep expertise in peptide drug discovery and metabolic disease research.